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Highlights 33 
 the interactions between CS:TPP nanoparticles and mucin were evaluated 34 
 the degree of interaction depends on the CS:TPP ratio, -potential and viscosity 35 
 a CS:TPP ratio of 4:1 displayed the strongest interaction with mucin 36 
 greater mucin binding efficiencies achieved at CS:TPP ratios of 4:1 and higher 37 
 a minimum CS:TPP ratio of 4:1 is required for stable interactions with mucin 38 
  39 
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Abstract 40 
Mucoadhesive molecules such as chitosan, can allow targeting of a particular tissue to prolong 41 
residence time and subsequently improve bioavailability. The purpose of this study was to 42 
investigate chitosan-tripolyphosphate (CS:TPP) nanoparticles and to evaluate the interaction 43 
between nanoparticles of different CS:TPP ratios with mucin using viscosity, particle size 44 
analysis and -potential. For all CS:TPP ratios examined, a minimum value of viscosity was 45 
reached for a 3:1 CS:TPP ratio, however chitosan nanoparticles at this ratio were not stable (< 46 
+30 mV), whereas a CS:TPP ratio of 4:1 displayed the strongest interaction. This suggests a 47 
minimum CS:TPP ratio of 4:1 is required to produce stable nanoparticles able to form strong 48 
interactions, which is consistent with a greater mucin binding efficiencies at CS:TPP ratios of 49 
4:1 and higher, which were quantified using a colorimetric assay. Further analysis of similar 50 
systems could lead potentially to tuneable chitosan nanoparticles for specific applications.   51 
 52 
Keywords: chitosan-tripolyphosphate (CS:TPP) nanoparticles; tuneable ionotropic gelation; 53 
mucoadhesiveness  54 
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1. Introduction  55 
A large number of polymers both natural (e.g. chitosan, alginate, guar gum, xanthan gum, 56 
pectin, etc.) and synthetic (e.g. Poly(ethylene oxide), Poly(acrylic acid), Poly(vinyl amine), 57 
etc.) have been studied for their mucoadhesive properties. Some of the reported advantages of 58 
these systems include targeting and localisation of the drug dosage form to a specific site, 59 
providing and area of intimate contact between the dosage form and the mucosa [1] and 60 
disadvantages include cytotoxicity, natural variations in both composition and molecular 61 
weight [2]. However, these disadvantages could be mitigated by the preparation of 62 
nanoparticles of controlled size and composition from an appropriate natural source for 63 
example chitosan.  64 
 65 
Chitosan (CS), is the second most abundant naturally occurring polymer on the planet, it is a 66 
nontoxic, biocompatible, biodegradable, cationic polysaccharide, which can be easily cross-67 
linked with tripolyphosphate (TPP polyanions) under mild conditions to form nanoparticles. 68 
Chitosan and chitosan nanoparticles (CSNPs) have been of particular interest in the 69 
pharmaceutical industry, for use in drug delivery systems especially in those, which target 70 
specific delivery sites as they demonstrate mucoadhesive characteristics. Amongst the different 71 
methods developed for the preparation of nanoparticles, ionotropic gelation with TPP is 72 
perhaps the simplest process and it can be easily optimised [3-7] to produce nanoparticles of 73 
the required particle size and charge such that the nanoparticles and any encapsulated drugs 74 
could penetrate the epithelial membrane [8] or interact with mucin in a controlled manner. 75 
Furthermore, the pH dependent solubility of chitosan enables tuneable pH-dependent release 76 
[9], which can be further tailored by derivatisation [10] or cross-linking (with TPP for example) 77 
as this would change the electrophoretic properties (net charge) [11] and nanoparticle size. 78 
Tuning the physical properties of nanoparticles can therefore, influence the pharmacokinetic 79 
profile of a loaded drug [12] and have an influence on the degree of mucin binding.  80 
 81 
Chitosan has great potential as a drug delivery vehicle due to its mucoadhesive behaviour, 82 
however the interactions of chitosan with mucus are complicated. In general, mucoadhesive 83 
drug delivery systems are designed with the aim of increasing the residence time of drugs at a 84 
specific site of absorption/action, to sustain drug release over a prolonged period and to 85 
minimize the degradation of drugs [13]. However, for specific applications it may be desirable 86 
to minimise nanoparticle-mucus interactions where the aim is for example, to rapidly penetrate 87 
mucosal barriers [14]. Therefore, controlling the physico-chemical properties of chitosan 88 
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nanoparticles (viscosity, charge and particle size, for example) via ionotropic cross-linking can 89 
be used as a method of controlling the strength of chitosan-mucus interactions [14].  90 
 91 
The components of mucus which are responsible for the viscous and elastic gel-like properties 92 
are mucins [15]. Mucins are a family of complex high molecular weight (5 - 20 x 105 g/mol) 93 
glycoproteins secreted by the epithelia of the intestinal, respiratory and urogenital tracts, 94 
consisting of linear or branched oligosaccharides attached to the protein core. These 95 
glycoproteins are mostly carbohydrate, which can account for 60 - 80 % of its weight. The 96 
carbohydrate fraction consists of five sugars N-acetyl-glucosamine, N-acetyl-galactosamine, 97 
galactose, and fucose and sialic acid (N-acetyl-neuraminic), as well as traces of mannose and 98 
sulfate esters [16, 17].  99 
 100 
The rigidity of the structure of mucin is mostly due to the high sialic acid and sulfate ester 101 
contents which leads to a negative charge on mucin which is the main reason for its gelling and 102 
mucoadhesive properties [18], although interactions with chitosan can vary depending on 103 
biological target tissues [19, 20]. Sialic acid, which is distributed throughout human tissues, is 104 
present in several fluids, including, cerebrospinal fluid, serum, urine, amniotic fluid saliva, and 105 
breast milk. Depending on the physiological conditions and physiochemical properties such as 106 
pH, the carboxylate group of sialic acid residues on mucin can interact with the positive charge 107 
on the chitosan particles, due to the protonated amino group (NH3+) to form electrostatic and 108 
hydrogen bonds [21]. Hydrophobic and hydrophilic interactions are also very important [22]. 109 
It is therefore clear that the surface charge (-potential), the size and occupied space (viscosity) 110 
of the nanoparticles will have an influence on their interactions with mucin. Previous studies 111 
which have attempted to alter the charge on chitosan nanoparticles have involved modification 112 
with poly-ethylene glycol for example [23] and have clearly demonstrated that mucin binding 113 
and drug release are influenced by nanoparticle charge [14, 23].   114 
 115 
In this study, once the different ratios (CS:TPP) of chitosan nanoparticles (CSNPs) were 116 
formulated their physico-chemical properties (viscosity, -potential, particle size and particle 117 
size distribution) were measured prior to being mixed with mucin. The physico-chemical 118 
properties were then determined after mixing, in order to examine the interaction between the 119 
chitosan nanoparticles and mucin. This provided an indication into how CS:TPP nanoparticles 120 
may act in vivo and which ratios of CS:TPP show potential as drug delivery vehicles. Moreover, 121 
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the mucoadhesiveness was then evaluated by measuring the mucin binding efficiency. It is 122 
therefore our hypothesis that by preparing CS:TPP nanoparticles of controlled viscosity, size 123 
and charge [3-7] it will be possible to determine whether a minimum CS:TPP ratio or net charge 124 
is required for mucoadhesion and from this gain a greater understanding of the mucoadhesive 125 
process. This will provide important information which would be in essential in designing 126 
tuneable mucoadhesive systems for specific applications, where for example, the degree of 127 
mucin binding should be controlled. 128 
 129 
2 Materials and Methods 130 
2.1 Materials 131 
Chitosan of low molar mass (LMW) of ∼ 50 000 g/mol as determined by capillary viscosity 132 
using equations 2-5 (see section 2.2.4.2), was purchased from Sigma–Aldrich (Gillingham, 133 
UK) and has an average degree of deacetylation (DD) of ∼90 % as determined by FT-IR using 134 
the equation 7 (see section 2.2.6). Glacial acetic acid and tripolyphosphate in the sodium salt 135 
form were also obtained from Sigma–Aldrich (Gillingham, UK). Extensively degraded pig 136 
gastric mucin was a kind gift from Biofac A/S (Kastrup, Denmark) and has been fully 137 
characterized previously in our group [17]. This product may differ slightly from the native 138 
porcine mucus gel due to the manufacturing process. However, off-the-shelf mucin 139 
formulations are often used research as they have similar functionality [24, 25] and it is 140 
expected that batch-to-batch variability would be less of an issue compared to freshly prepared 141 
material [24]. All materials were used without any further purification.     142 
 143 
2.2 Experimental 144 
2.2.1 Preparation of chitosan and TPP solutions 145 
A 1.0 mg/mL solution of TPP was prepared in deionized water and the pH of this solution was 146 
adjusted by adding 0.1 N hydrochloric acid (HCl) until a final pH of 5.0 was obtained. A 3.0 147 
mg/mL solution of chitosan was dissolved in dilute acetic acid (0.5 %) and this was left stirring 148 
overnight at room temperature. The solution was then filtered under Gooch crucible (AG 1 X 149 
3) vacuum filtration to discard any trace insoluble material then pH was adjusted to 5.0 using 150 
0.1 N sodium hydroxide (NaOH). 151 
 152 
2.2.2 Preparation of chitosan: TPP nanoparticles 153 
CS:TPP nanoparticles were produced by the drop wise addition of appropriate volumes of 154 
chitosan solutions to appropriate volumes of TPP solutions under magnetic stirring at 600 rpm 155 
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for 60 min, resulting in CS:TPP ratios of 3:1, 4:1, 5:1, 6:1 and 7:1 respectively. All operations 156 
above were conducted at room temperature and mixtures were sonicated for 5 min (the cycle 157 
and amplitude was adjusted to 0.5 and 80 % respectively; Hielscher Ultrasonics GmbH, 158 
Teltow, Germany) before being subjected to further analysis. 159 
 160 
2.2.3 Mucin sample preparation 161 
A 3.5 % (w/v) mucin stock solution was formulated using 3.5 g of mucin to 100 mL of 162 
deionised water (pH 4.2). This was magnetically stirred overnight at room temperature (~20 163 
°C). The solution was then filtered through filter paper (Whatman No.1, Sigma–Aldrich 164 
Gillingham, UK). 165 
 166 
2.2.4 Evaluation of the mucoadhesive properties of chitosan-TPP nanoparticles 167 
2.2.4.1 Adsorption of mucin on to chitosan-TPP nanoparticles 168 
Mucin solution (1 mL) was added to each CS:TPP nanoparticle preparation (19 mL), with 169 
magnetic stirring at 600 rpm and mixtures were incubated at 37 °C for 1 h prior to analysis. 170 
The mucin-nanoparticle mixtures were then centrifuged at 40 000 x g for 60 min and the 171 
supernatant was used to measure the free mucin concentration using the standard calibration 172 
curve (see section 2.2.5). In addition, the mucoadhesiveness was expressed as the mucin 173 
binding efficiency of the nanoparticles and was calculated from the following equation:  174 
 175 
ܯݑܿ݅݊ ܾ݅݊݀݅݊݃ ݂݂݁݅ܿ݅݁݊ܿݕ  (%)  = (஼௢ – ஼௦) 
஼௢
× 100                                              Eq. (1) 176 
 177 
where Co is the initial concentration of mucin used for incubation, and CS is the concentration 178 
of free mucin in the supernatant [26, 27]. 179 
 180 
2.2.4.2 Viscosity analysis of chitosan nanoparticles-mucin mixtures 181 
The relative viscosity (ηrel) of all samples (chitosan solution, mucin solution and chitosan 182 
nanoparticle-mucin mixtures) were tested at 37.0 ± 0.1 °C by a Bohlin Gemini HR Nano 183 
Rheometer (Malvern Instruments, Worcestershire, UK) using 1 mm gap and 55 mm parallel 184 
plate geometry at a constant shear rate of 500 s−1 under precise temperature control, according 185 
to the following equation: 186 
 187 
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 rel
 Eq. (2) 188 
 189 
where η is the average viscosity of the samples and, ηo is the average viscosity for the reference 190 
solvent i.e. dilute acetic acid (pH 5). All measurements were performed in triplicate.  191 
 192 
The specific (sp), viscosity is defined as follows:  193 
 194 
1 relsp   Eq. (3) 195 
 196 
A useful method for measuring the intrinsic viscosity is to calculate the relative and specific 197 
viscosities at one concentration and utilise the Solomon-Ciutâ approximation [28, 29]. The 198 
intrinsic viscosity can then be accurately estimated (error generally ~1 %) by a single 199 
measurement at low concentration approximately ≤ 0.5 %.  200 
 201 
    
c
relsp
2/1ln22 



 Eq. (4) 202 
 203 
We can then convert intrinsic viscosities to molar mass using the following Mark–Houwink–204 
Kuhn–Sakurada (MHKS) power law relationship [30]: 205 
 206 
ܯݓ = ( [ఎ]
଴.଴଴଻ସ
)ଵ ଴.ଽହൗ   Eq. (5) 207 
 208 
A change in relative viscosity of nanoparticles indicates the interaction with mucin [31]. This 209 
information can then be used to give a quantitative estimation of the degree of interaction, by 210 
comparing the value for the relative viscosity with a theoretical value based on there being no 211 
interaction between the nanoparticles and mucin calculated using equation 6. In order to gain 212 
a fuller understanding of this interaction samples were not filtered prior to measurement. 213 
  214 
 215 
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rel (theoretical) = (rel (mucin) x fraction of mucin) + (rel (nanoparticles) x fraction of nanoparticles)  216 
Eq. (6) 217 
 218 
where the fraction of mucin ranged from 0.49 - 0.57 and the fraction of nanoparticles was 0.43 219 
- 0.51 based on the amount of chitosan in the formulation.  220 
 221 
In the case of no interaction the difference between the theoretical and calculated relative 222 
viscosity is zero [31]. The relative deviation from the theoretical additive line (or line of “no 223 
interaction”) gives a quantitative estimate of mucoadhesion [32], although the formation of 224 
insoluble complexes/ coacervates can lead to difficulty in interpretation [33].  225 
 226 
2.2.4.3 Zeta potential of chitosan nanoparticles-mucin mixtures 227 
The -potential of the chitosan solution (0.3 %), mucin solution (3.5 %) and chitosan 228 
nanoparticle-mucin mixtures were measured with a Malvern Zetasizer Nano-Z (Malvern 229 
Instruments Limited, Malvern, UK) using the capillary cell. All measurements were taken at 230 
37.0 ± 0.1 °C and the mean values and standard deviations of triplicate measurements were 231 
calculated. Mucin solutions were measured at pH 4.2 and CS:TPP nanoparticle-mucin mixtures 232 
were at pH 5. 233 
 234 
2.2.4.4 Particle Size analysis of chitosan nanoparticles-mucin mixtures 235 
The particle diameter of mucin solution (3.5 %) and chitosan nanoparticle-mucin mixtures were 236 
measured by dynamic light scattering (DLS) using a Malvern Zetasizer Nano-Z (Malvern 237 
Instruments Limited, Malvern, UK). The dispersion medium (water) and refractive index of 238 
particles was set at 1.330 and 1.6 respectively. A glass cuvette was used and the angle of 239 
scattering was 173°. The samples were measured in triplicate and the results represent the mean 240 
particle diameter at 37.0 ± 0.1 °C. Mucin solutions were measured at pH 4.2 and CS:TPP 241 
nanoparticle-mucin mixtures were at pH 5. 242 
 243 
2.2.5 Mucin adsorption assay 244 
Mucin adsorption was studied using a periodic acid /Schiff colorimetric method described by 245 
Mantle and Allen [34] to determine the free mucin concentration following incubation with 246 
chitosan nanoparticles. This method was divided into two steps: firstly, periodic acid reagent 247 
was prepared by adding 10 μL of 50 % of periodic acid solution to 7 mL of 7 % acetic acid 248 
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solution. Secondly, the preparation of the Schiff reagent was prepared by adding 1 % basic 249 
Fuschin aqueous solution to 20 mL of 1 M HCl, and twice mixing the resulting solution with 250 
300 mg of activated charcoal. Sodium metabisulfite (0.1 g per 6 mL of Schiff reagent) was 251 
added directly before use and the resultant solution was incubated at 37 °C until it became 252 
colourless or pale yellow (about 90 min). A standard calibration curve was constructed by 253 
adding 200 µL of freshly prepared periodic acid reagent to 2 mL of mucin standard solutions 254 
(0.01 % – 0.08 %), solutions then were incubated at 37 °C for 2 h in a water bath to complete 255 
periodate oxidation. Then 200 µL of the colourless Schiff reagent was added at room 256 
temperature in order to react with the aldehyde (from first step) to form a pink coloured 257 
solution. Colour development was complete after 30 min and the absorbance of the standard 258 
solutions was measured at 555 nm using UV-Vis spectrophotometer (Shimadzu UV-160A, 259 
Wolverton, UK). Samples were prepared for analysis as per section 2.2.4.1. 260 
 261 
2.2.6 Fourier transform infrared (FTIR)  262 
Spectroscopy FTIR spectra of chitosan, were recorded using a Fourier transform infrared 263 
spectrophotometer (Thermo Nicolet 380 FT-IR spectrometer, Thermo Fisher Scientific, 264 
Loughborough, UK), operating from 4000 to 400 cm-1. The degree of deacetylation (DD) was 265 
calculated from equation 7 [35]. 266 
 267 
ܦܦ (%) = 100 − (
൬ಲభలఱఱ೎೘
షభ
ಲయరఱబ೎೘షభ
൰௫ ଵ଴଴
ଵ.ଷଷ
)       (Eq. 7) 268 
 269 
where A1655 cm-1 and A3450 cm-1 are the areas under the absorbance peaks for the C=O and OH 270 
stretches, respectively.  271 
 272 
2.3 Statistical analysis 273 
All experiments were expressed as the mean value ± standard deviations (SD) of at least three 274 
readings. Statistical significance (p <0.05) between test groups was performed by one-way 275 
analysis of variance (ANOVA) and a Tukey post-hoc test. 276 
 277 
3 Results and discussion 278 
Chitosan was dissolved in glacial acetic acid at pH 5, below its pKa 6.2–6.5, to produce a 279 
reactive positively charged ammonium group (NH3+) (protonated amine D-glucosamine 280 
11 
 
monomeric unit). Due the different pKa values 0.9, 1.9, 5.3, 7.7 and 9.5 ([36, 37], multiple 281 
anions (P3O105−, HP3O104−, H2P3O103−, H3P3O102− and H4P3O10−) may be present in solution 282 
depending on the pH when TPP is dissolved in water, which is undesirable as they can 283 
competitively react with the protonated ammonium groups (NH3+) of chitosan solution (pH 284 
5.0). Therefore, the pH of TPP was adjusted to 5.0 to make sure that predominantly H2P3O103− 285 
(~67%) ions exist in solution; this is also beneficial in producing less polydisperse 286 
nanoparticles [38]. The formation of chitosan nanoparticles (CSNPs) by ionic gelation occurs 287 
spontaneously upon the interaction with the TPP anion solution with the cationic chitosan 288 
solution (ammonium groups, NH3+). Five different ratios of (CS:TPP) nanoparticles (3:1, 4:1, 289 
5:1, 6:1 and 7:1) were spontaneously obtained upon addition of a TPP (polyanion) solution to 290 
the chitosan solution (polycation). These formulations resulted in positively charged chitosan 291 
nanoparticles, which should facilitate electrostatic interactions with the negatively charged 292 
carboxylic acid groups of the mucin. Studies on native pig gastric mucin have previously shown 293 
an isoelectric point at ∼pH 2–2.5 [39] and sialic acid has a pKa of 2.6 [40]. Therefore, there is 294 
potential to interact with the positive charged amino groups of chitosan nanoparticles [41] when 295 
both sialic acid and chitosan are oppositely charged at therefore ~ pH 4.5 - 5.  However, other 296 
contributions from, for example, hydrogen bonding and hydrophobic interactions may also 297 
have an effect. 298 
 299 
3.1 Mucoadhesion studies 300 
The mucoadhesive properties and the influences of different CS:TPP ratio at 3:1, 4:1, 5:1, 6:1 301 
and 7:1 nanoparticles were evaluated by measuring the relative viscosity, particle size and 302 
change of -potential on interaction with negatively charge mucin. Chitosan nanoparticle 303 
mixing with mucin was used to assess the stability and interaction of nanoparticles prepared 304 
using various CS:TPP ratios and mucin which could lay the foundations for potential future 305 
use as a drug carrier and/ or other pharmaceutical applications. All formulations were based on 306 
the measurements of the viscosity, -potential (surface charge) and particle size of chitosan 307 
nanoparticles before and after incubation with mucin at 37 °C under moderate stirring.  308 
 309 
3.1.1 Assessment of chitosan nanoparticle-mucin interactions by relative viscosity  310 
The interactions between chitosan nanoparticles (CS:TPP) and mucin were initially studied by 311 
relative viscosity (ηrel). Chitosan solution (0.3 %) and mucin solution (3.5 %) were prepared in 312 
order to produce a relative viscosity (ηrel) close to 1.8. Relative viscosities of this order of 313 
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magnitude are required as at higher relative viscosities for example >2 the onset in polymer 314 
entanglement is observed. Therefore, the relative viscosities were kept below two with the aim 315 
of minimising these polymer entanglement effects, which would obscure changes in viscosity 316 
due to interactions with mucin [42]. 317 
 318 
Figure 1: Relative viscosity of mucin, chitosan, native chitosan nanoparticles (black columns) 319 
and chitosan nanoparticle-mucin mixtures (white columns) at 37 °C. All values represent the 320 
mean ± 2SD (n = 3). The deviations from the theoretical viscosity of no interaction were -27.7, 321 
-25.5, -24.9, -23.3 and -20.6 % for CS: TPP ratios of 3:1, 4:1, 5:1, 6:1 and 7:1, respectively. 322 
 323 
When chitosan nanoparticles were mixed with mucin at different CS:TPP ratios (3:1, 4:1, 5:1, 324 
6:1 and 7:1), the formation of chitosan nanoparticles-mucin interaction products were 325 
determined on the basis of the changes in relative viscosities of the nanoparticle-mucin 326 
mixtures [43]. The relative viscosity of chitosan nanoparticle (CS:TPP)-mucin mixtures 327 
increased with increasing CS:TPP ratios (Figure 1).  328 
 329 
Increasing the CS:TPP ratio (no mucin), caused an increase in relative viscosity which was 330 
expected due to the increased concentration of chitosan used (higher charge on chitosan 331 
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nanoparticles) [44, 45]. It was observed however, that chitosan nanoparticle-mucin mixtures 332 
decreased the relative viscosities compared with CS:TPP nanoparticles (blank). This could be 333 
due to the electrostatic interactions between positively charged ammonium group on the 334 
chitosan nanoparticles and the negatively charged sialic acid residue on mucin, perhaps with a 335 
contribution from hydrogen bonds. The difference between the native chitosan nanoparticle 336 
and chitosan nanoparticle-mucin mixture was not statistically significant (p > 0.05) on relative 337 
viscosity at (CS:TPP) 3:1. This could be attributed to a small amount of chitosan nanoparticles 338 
interacting with the mucin causing a limited viscosity change.  However, other CS:TPP ratios 339 
(4:1, 5:1, 6:1 and 7:1) did significantly affect relative viscosity (p < 0.05), where the largest 340 
absolute decrease in relative viscosity is at CS:TPP ratio of 6:1. The percentage deviation from 341 
theoretical line of no interaction is similar for all ratios (~ -25 %), albeit the deviation is less in 342 
nanoparticles with higher CS:TPP ratios. A percentage deviation of ~ -25 % is consistent with 343 
native chitosan-mucin interactions in the presence of salt [31]. This suggests an important 344 
interaction occurring between chitosan nanoparticles and mucin. This observed reduction in 345 
relative viscosity and the increased deviation from the “no interaction” line is consistent with 346 
a reduction in the concentration of macromolecules in solution (e.g. the formation of a 347 
precipitate [46], which was observed when mucin was mixed with CS:TPP nanoparticles in 348 
larger amounts (data not shown)). However, in this case it is most likely due to a conformational 349 
change to a more compact structure (i.e. a reduction in the hydrodynamic volume [32]) for one 350 
or more of the macromolecules due to an interaction [6, 31, 32]. The latter would be consistent 351 
with a decrease in net charge/ -potential [47]. A decrease in viscosity may also be 352 
advantageous from a formulation point of view, for example in ocular delivery systems where 353 
an increase in viscosity would be unacceptable due the blink process requiring low shear 354 
viscosities in order to avoid unnecessary damage to the corneal epithelium [41], low viscosity 355 
aids the sprayability of liquid nasal formulations [21, 32]. Although not explicitly evaluated, 356 
changes in viscosity are related to the swelling and stiffness of polymeric systems and could 357 
therefore be probed further, this would be influenced greatly by the CS:TPP ratio and the pH 358 
at which nanoparticles were formed [37] where chain stiffness has been shown to influence 359 
mucin interactions [31, 32]. 360 
 361 
3.1.2 Zeta potential of chitosan nanoparticles-mucin mixtures  362 
In order to further support the interactions between chitosan nanoparticles and mucin, -363 
potential were investigated. Determination of the -potential of chitosan nanoparticles in the 364 
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presence of mucin has been demonstrated to be a good means of studying the mucoadhesive 365 
interactions of the chitosan nanoparticle–mucin mixtures [24, 25, 31]. Furthermore, -366 
potentials of less than +30 mV indicate lower chitosan nanoparticle stability due to lower 367 
electrostatic repulsion, however, -potential of native chitosan nanoparticles increased linearly 368 
(r2 > 0.99) as the CS:TPP ratio is increased (Figure 2) which is a highly attractive property 369 
amongst nanoparticles. Furthermore, this would theoretically allow the preparation of 370 
nanoparticles of controlled -potential in the range +34 - +42 mV by varying the CS:TPP ratio. 371 
Nanoparticles outside of this range could be prepared under different pH conditions or by using 372 
different CS:TPP ratios, for example. 373 
 374 
Figure 2: Zeta potential values obtained for mucin, chitosan and native chitosan nanoparticles 375 
(black columns) and chitosan nanoparticle-mucin mixtures (white columns) at 37 °C. All 376 
values represent the mean ± 2SD (n = 3). 377 
 378 
Chitosan has a mucoadhesive properties, therefore it would be expected that the surface charge 379 
of chitosan nanoparticles might be changed by the adhesion of mucin and in this case a decrease 380 
in -potential was observed upon mixing with mucin at all CS:TPP ratios (Figure 2). The 381 
occurrence of such change was detected by measuring the changes in -potential of chitosan 382 
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nanoparticle-mucin mixtures with different of CS:TPP ratios. The -potential of mucin and 383 
chitosan were -4 ± 3 and +46.7 ± 0.4 mV, respectively. It is known that chitosan has positive 384 
charge at this pH due to presence of ammonium ions (NH3+) [48]. The negative charge, 385 
however, of mucin is as a result of the ionization of sialic acid (COO-). Therefore, chitosan 386 
nanoparticles could lead to a strong electrostatic interaction with the mucin. An addition of 387 
mucin to the different ratios of CS:TPP nanoparticles results in a significant (p < 0.05) decrease 388 
in -potential for all CS:TPP ratios, except 3:1 (Figure 2). The reduction of -potential could 389 
be due to the ionic interaction between negatively charged sialic acid in mucin and positively 390 
charged amino groups in chitosan nanoparticles [49]. Moreover, as shown in Figure 2, the -391 
potential decreased sharply as the CS:TPP ratio decreased from mixtures 4:1 to 3:1, which 392 
might be caused by the decreased amount of chitosan in these nanoparticles which leads to 393 
most of the NH3+ groups interacting with COO- groups on the sialic acid. These results were in 394 
agreement with lowest relative viscosity of 3:1 mixture (Figure 1). Furthermore, this may be 395 
attributed to the fact that native (3:1) ratio nanoparticles had lower -potential values (+34.7 396 
mV) than other ratios including 4:1, 5:1, 6:1 and 7:1. On the other hand, a small increase in -397 
potential of chitosan nanoparticle-mucin mixtures was observed as the CS:TPP ratio increased 398 
from 5:1 to 7:1, which might be due to increase positive charge surfaces on the particles. This 399 
may also be confirmed by the changes in particle size and polydispersity index (PDI) of native 400 
CS:TPP nanoparticles. At all CS:TPP ratios greater than 3:1 the -potential decreased by ~ 5 401 
mV which is in the range of the overall charge on mucin and may be indicative of the majority 402 
of the mucin being bound to the nanoparticles at these ratios.  403 
 404 
3.1.3 Particle size of chitosan nanoparticle-mucin mixtures  405 
In all cases there is an increase in particle size upon addition of CS:TPP nanoparticles to mucin, 406 
clearly indicating an interaction (Table 1), although this increase in particle size is generally 407 
not as pronounced when the CS:TPP nanoparticles are larger i.e. those containing greater 408 
amounts of chitosan [2]. This is consistent with the smaller deviation from the no interaction 409 
line for CS:TPP nanoparticles containing larger amounts of chitosan. The change in -potential 410 
is related to a change particle size [21] and it is clear that as the CS:TPP ratio increases both 411 
the -potential and particle size also increase. This is true both in the presence and absence of 412 
mucin which is related to the reduction in TPP available to interact with chitosan and therefore 413 
a decrease in the density internal cross-linking and hence larger particles [50] (Table 1). 414 
Nanoparticles at all ratios, other than 3:1, were in the optimal range (200 – 500 nm) for mucosal 415 
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interaction [51]. When the mucin solutions were mixed with different CS:TPP ratios from 3:1 416 
to 7:1, the particle size increased significantly (Table 1), This is probably due to adsorption 417 
(binding) of mucin on the chitosan nanoparticle surfaces [24]. In addition, the increase in 418 
particle size, together with a decrease in -potential demonstrates that the mucin is binding to 419 
the surface of the chitosan nanoparticles, when the CS:TPP ratios varied from 3:1 to 7:1. This 420 
result may be attributed to the overall negative charge of mucin, due to the presence of sialic 421 
acid, and the overall positive charge of the chitosan nanoparticles. The interaction at the 422 
CS:TPP ratio (4:1) between CSNPs and mucin was the strongest as the nanoparticles binding 423 
the mucin more strongly and hence reducing the particle size.  424 
 425 
Table 1: Particle size and polydispersity index of chitosan TPP nanoparticles (CSNPs) in the 426 
presence and absence of mucin. 427 
Sample Mean particle size (nm) 
± 2 standard deviations 
Polydispersity index (PDI) 
± 2 standard deviations 
Mucin 41 ± 5 0.48 ± 0.02 
   
CSNPs   
3:1 195 ± 16g 0.30 ± 0.02b,c 
4:1 216 ± 8g 0.22 ± 0.03c 
5:1 247 ± 4f 0.24 ± 0.00b,c 
6:1 283 ± 8e 0.25 ± 0.02b,c 
7:1 293 ± 22d,e 0.27 ± 0.03b,c 
   
CSNPs with mucin   
3:1 336 ± 14b,c 0.44 ± 0.05a 
4:1 305 ± 19d 0.29 ± 0.08b,c 
5:1 332 ± 12c 0.31 ± 0.07b,c 
6:1 356 ± 8b 0.30 ± 0.02b,c 
7:1 387 ± 30a 0.35 ± 0.05a,b 
Means sharing the same letters in a column are not significantly (p > 0.05). 428 
 429 
Furthermore, this increase in interaction is important in respect to potential applications as 430 
increased interaction with mucin is indicative of increased mucoadhesion, which depending on 431 
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the specific application may not always be optimum. At the lowest CS:TPP ratio (3:1) mucin 432 
in mixture is potentially available in greater amounts. Therefore, we would expect more mucin 433 
to be adsorbed on to the chitosan nanoparticle surface, which would increase aggregation due 434 
to, for example, the formation of mucin bridges between chitosan nanoparticles [24], or the 435 
aggregation of nanoparticles due to their instability the latter is consistent with the low -436 
potential value of the 3:1 mixture (+22.6 mV). The PDI value was used as a reflection of 437 
uniformity and stability of particles [50]. Moreover, the highest value (0.44) of PDI at CS:TPP 438 
ratio 3:1 mixture indicated a wider range of particle size distribution in chitosan nanoparticle-439 
mucin mixtures relative to other CS:TPP ratios. At a CS:TPP ratio of 4:1 mucin mixture, 440 
chitosan nanoparticles with the smallest size and lower PDI were formed. Above the CS:TPP 441 
ratio 4:1 mixture, a clear increase in chitosan nanoparticle-mucin mixture size is obtained, 442 
thereby confirming the adsorption of negative mucin onto the surface of the chitosan 443 
nanoparticles. In addition, as is shown in Table 1, the CS:TPP ratios from 5:1 to 7:1 mixtures 444 
have PDI values of 0.30 - 0.35, indicating a narrow size range and a homogenous dispersion of 445 
chitosan nanoparticle-mucin mixtures were obtained [52]. This is important in terms of the 446 
movement/ diffusion of nanoparticles through a mucosal layer in vivo [53]. On the basis of 447 
these observations, the strongest interaction, which can be related to the smallest particle size 448 
was a CS:TPP ratio of 4:1. 449 
  450 
3.2 Mucin binding test (adsorption) as indicator of mucoadhesiveness 451 
3.2.1 Mucin colorimetric assay and calibration curve 452 
The colorimetric assay described in section 2.2.5 was used to provide an effective method of 453 
detection and analysis of mucin glycoproteins. This assay showed a high sensitivity with LOD 454 
and LOQ being <0.01 and <0.02 %, respectively with a high linearity (R2 > 0.99) and 455 
reproducibility: RSD < 3.7 % (data not shown). 456 
 457 
Mucin is predicted to spontaneously adsorb onto the surface of the chitosan nanoparticles [52]. 458 
The mucoadhesive behaviour of chitosan nanoparticles was assessed by the suspension of 459 
different CS:TPP ratios in a fixed amount of mucin in aqueous solution at 37 °C. Furthermore, 460 
the amount of mucin adsorbed was measured from the change in free concentration of mucin 461 
in the reaction mixtures according to Eq. 1.  462 
 463 
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After confirming the high surface charge (-potential > +30 mV) for all native CS:TPP ratios 464 
(Figure 2), a mucin binding efficiency assay was applied to confirm the system’s adhesiveness 465 
(Figure 3). 466 
 467 
Figure 3: Mucin binding efficiency (adsorption) of chitosan nanoparticles of different CS:TPP 468 
ratios. All values represent the mean ± 2SD (n = 3). 469 
 470 
The mucin binding efficiency (mucin adsorbed onto the chitosan nanoparticle surface) 471 
increased from 80 ± 3 % to 89 ± 5 % (p < 0.05) as CS:TPP ratio increased from 3:1 to 4:1 472 
(Figure 3). However, it was demonstrated that, there were no significant differences (p > 0.05) 473 
in the mucin binding efficiency values (~95 %) when increase in CS:TPP ratios from 5:1 to 474 
7:1. This result may be attributed to more NH3+ functional groups being present to interact with 475 
the sialic acid residues on mucin. This also agrees with the findings from -potential which 476 
suggests a large amount of mucin has been bound to the nanoparticles at CS:TPP ratios greater 477 
than 3:1 and that native CS:TPP nanoparticles of ratios from 5:1 to 7:1 were shown to have 478 
more available surface charges (> +39 mV).  Based on these observations the chemical 479 
interaction between the CS: TPP nanoparticles is shown diagrammatically in Figure 4. In this 480 
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very simplistic model the CS:TPP is shown as a spherical particle, although this is generally 481 
not the case [54].  482 
 483 
Figure 4: Diagrammatic representation of the interaction between CS:TPP nanoparticles and 484 
mucin. For simplicity and clarity, the CS:TPP nanoparticles are represented as spheres with 485 
chitosan residues on the exterior and only the negatively charged sialic acid residues are shown 486 
in the mucin (N.B. sizes of residues and nanoparticles are not to scale). Adapted from [55]. At 487 
lower CS:TPP ratios, for example 3:1 there will be less chitosan (positive charge) on the 488 
nanoparticle surface which may lead to an excess of mucin and potentially aggregation due to 489 
mucin bridges between nanoparticles [56] or due to nanoparticle instability if the zeta potential 490 
is in the range -30 mV – +30 mV. 491 
 492 
It is known that the smaller particles are able to penetrate to the sub-mucosal layers whereas 493 
the larger particles are localised in the epithelial lining [57]. Based on our results an optimal 494 
minimum chitosan nanoparticle CS:TPP ratio of 4:1 is required to interact with mucin, 495 
nanoparticles with lower amounts of chitosan are unstable and prone to aggregation. The -496 
potential of 4:1 mixture is +31.3 mV (Figure 2), its particle size is the smallest and has lowest 497 
PDI value (Table 1). At 4:1 there are sufficient levels of CS:TPP particles for the mucin to 498 
interact with. This result may be attributed to a critical point of binding to sialic acid being 499 
saturated at the CS:TPP ratio of 4:1 and all of the mucin being adsorbed on to the particles. 500 
Although not significant statistically the CS:TPP ratio of 6:1 appears to be particularly 501 
interesting as at this ratio there is the greatest difference in relative viscosity upon the 502 
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interaction with mucin (although not the greatest deviation from the additive line), and there is 503 
also the smallest change in zeta potential, particle size and polydispersity index and may be 504 
related to decreased mucoadhesion at larger particle sizes [2]. 505 
 506 
4 Conclusions 507 
In this study, CS:TPP nanoparticles of different ratios, prepared by the ionotropic gelation 508 
method, were evaluated for their mucoadhesive properties for potential use as in 509 
pharmaceutical applications. The incubation (at 37 °C) of CS:TPP nanoparticles solutions of 510 
different CS:TPP ratios from 3:1 - 7:1 with mucin led to a modification in their physiochemical 511 
properties such as decreased -potential and increased particle size.  512 
 513 
For all CS:TPP ratios examined, a minimum value of viscosity was reached for a 3:1 CS:TPP 514 
ratio, however chitosan nanoparticles at this ratio (3:1) were not stable (-potential < +30 mV), 515 
whereas a CS:TPP ratio of 4:1 displayed the strongest interaction with mucin (greatest 516 
deviation from the interaction additive line). Taken all together we can conclude that a 517 
minimum CS:TPP ratio of 4:1 is required to produce stable nanoparticles able to form strong 518 
interactions with mucin, which is consistent with a greater mucin binding efficiency at CS:TPP 519 
ratios of 4:1 and higher. Clearly, the potential ability to fine tune the physico-chemical 520 
properties (viscosity, charge and size) of chitosan nanoparticles demonstrates that cross-linking 521 
with tripolyphosphate could lead to advances in transmucosal drug delivery. Further analysis, 522 
including for example drug release kinetics and swelling properties of CS:TPP nanoparticles 523 
should be the next step in this process and would ideally lead to tuneable chitosan nanoparticles 524 
for specific drug delivery applications.   525 
 526 
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